Literature DB >> 10708087

Low-friction arthroplasty with Boneloc bone-cement: outcome at 2 to 4 years.

J P Walczak1, J C D'Arcy, K R Ross, S E James, A V Bonnici, S R Koka, R W Morris.   

Abstract

We report the clinical and radiologic outcome of 109 Chamley low-friction arthroplasties implanted with Boneloc bone-cement (Biomet, Bridgend, South Wales, UK) into 104 patients. The mean follow-up was 30 months (range, 2-48 months). There were 72 women (mean age, 71 years) and 32 men (mean age, 72). Cartridge-packed cement was used in 37 cases and vacuum-packed cement in 72 cases. Survivorship analysis based on revision for aseptic loosening showed 79% survival at 4 years. Seventeen (15.5%) hips have been revised for aseptic loosening to date, in which all stems and 4 cups were loose. Extensive femoral osteolysis was always present and resulted in 4 cases of femoral cortical perforation at revision. Survivorship analysis based on revision and radiologic failure showed only 55% survival over the same period. When radiologic loosenings were included as failures, the vacuum-packed cement performed significantly worse than the cartridge-packed cement it replaced. These poor results were consistent with the withdrawal of Boneloc from clinical use in 1995, and we recommend indefinite follow-up for surviving prostheses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708087     DOI: 10.1016/s0883-5403(00)90264-x

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  Factors affecting the mechanical and viscoelastic properties of acrylic bone cement.

Authors:  A J C Lee; R S M Ling; Sabina Gheduzzi; Jean-Pierre Simon; R J Renfro
Journal:  J Mater Sci Mater Med       Date:  2002-08       Impact factor: 3.896

2.  Creep and fatigue behavior of a novel 2-component paste-like formulation of acrylic bone cements.

Authors:  Ulrike Köster; Raimund Jaeger; Mareike Bardts; Christian Wahnes; Hubert Büchner; Klaus-Dieter Kühn; Sebastian Vogt
Journal:  J Mater Sci Mater Med       Date:  2013-04-06       Impact factor: 3.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.